Targeting BCL-2 in Leukemia:
We utilize state-of-the-art technology BH3 profiling to determine sensitivity to apoptosis and anti-apoptotic dependencies for discovering targeted therapeutics in diverse types of leukaemia.
Identifying novel therapeutics in chemoresistant breast cancer:
We screened over 30,000 small molecules to find novel therapeutics that kill chemoresistant triple negative breast cancer but that do not kill normal cells. Currently, we are using advanced proteomic approaches to determine mechanisms of action of the novel compounds.